| 1 |
Molecular glues are the latest craze in pharma research, but what are they? |
| 2 |
Early AMR pipeline looks beyond traditional antibiotics |
| 3 |
Merck to invest €300m in South Korean bioprocessing centre |
| 4 |
Bionomics to advance non-SSRI PTSD candidate to Phase III |
| 5 |
Keytruda combination treatment for NSCLC falls short in Phase III |
| 6 |
Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns |
| 7 |
BMS’ cell therapy Abecma gains EC approval for multiple myeloma |
| 8 |
Lonza to acquire Roche biologics manufacturing site for $1.2bn |
| 9 |
IO360: first allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma |
| 10 |
IO360: Motixafortide shows Phase II efficacy in first-line pancreatic cancer |
| 11 |
PD-1 inhibitors and systemic oncolytic viral immunotherapies under the spotlight at IO360 |
| 12 |
FDA approves Wegovy for reducing risk of cardiovascular death |
| 13 |
NVIDIA doubles down on AI in healthcare with drug discovery deals |
| 14 |
Microsoft and NVIDIA expand collaboration in healthcare innovation |
| 15 |
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment |
| 16 |
Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech |
| 17 |
Tierra raises $11.4 in Series A round for predictive AI protein maker |
| 18 |
Cell & gene therapy: the leading companies in recombinant AAV gene therapy revealed |
| 19 |
Leading clinical trials companies in the artificial intelligence theme |
| 20 |
Q4 2023 update: immuno-oncology related M&A activity in the pharmaceutical industry |
| 21 |
Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval |
| 22 |
Pharmaceutical drug delivery market and systems |
| 23 |
Pharmaceutical consulting companies, pharmaceutical training and other development services |
| 24 |
Leading providers of washing, disinfection and sterilisation equipment and services |
| 25 |
Leading providers of product inspection, testing and detection equipment and services |
| 26 |
Pharma Technology Focus |
28121
